David K. Lee, CEO of Servier Pharmaceuticals, shared Servier Pharmaceuticals’s post on LinkedIn, adding:
“Since Servier’s founding in the U.S. in 2018, our team has been steadfastly dedicated to advancing care for patients with rare cancers. Today marks another milestone in this journey with the signing of the transaction to acquire Day One Biopharmaceuticals.
We look forward to advancing their marketed product and integrating their targeted therapy portfolio into Servier’s already extensive oncology pipeline.”
Quoting Servier Pharmaceuticals‘ post:
“Today, Servier announced the acquisition of Day One Biopharmaceuticals, an important step in advancing care for low-grade glioma patients and accelerating innovation for people living with a rare cancer.”
Other articles featuring David K. Lee and Servier Pharmaceuticals on OncoDaily.